Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Catechol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | FYN | P06241 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Catechol SCHEMBL8411371 | 1.00 | CA2 (0.62) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL27477125 | 0.97 | CA2 (0.59) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL28266919 | 0.92 | CA2 (0.53) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL2555536 | 0.90 | KDM4E (0.67) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL4622850 | 0.88 | CA2 (0.56) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL10659163 | 0.88 | KDM4E (0.62) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL27240704 | 0.87 | MAPT (0.48) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL154583 | 0.87 | ALDH1A1 (0.71) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL30530338 | 0.87 | ALDH1A1 (0.71) | CA2ALDH1A1HPGDCA12CA14 | |
| Catechol SCHEMBL21196902 | 0.87 | ALDH1A1 (0.71) | CA2ALDH1A1HPGDCA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115895800-B | Semi-water-based wafer substrate cleaning fluid composition and method of use | 芯越微电子材料(嘉兴)有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-115895800-A | Semi-aqueous wafer substrate cleaning solution composition and application method thereof | 芯越微电子材料(嘉兴)有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20020045584-A1 | Acyclic isoprenoid ether derivatives as chemotherapeutics | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-04-18 | — | — | US | claimed |
| WO-2002005856-A2 | ACYCLIC ISOPRENOID ETHER DERIVATIVES AS CHEMOTHERAPUETICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-01-24 | — | — | WO | claimed |
| CN-115895800-B | Semi-water-based wafer substrate cleaning fluid composition and method of use | 芯越微电子材料(嘉兴)有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-117700565-A | Recovery of component cellulose esters | 伊士曼化工公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-114072429-B | Recovery of component cellulose esters | 伊士曼化工公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-115895800-A | Semi-aqueous wafer substrate cleaning solution composition and application method thereof | 芯越微电子材料(嘉兴)有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-113813406-B | Nano-particles for treating atherosclerosis by MRI and chemical excitation photodynamic therapy | 南京鼓楼医院 | 2023-03-24 | — | — | CN | disclosed |
| CN-114681661-B | Hemostatic powder and preparation method thereof | 四川大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-114072429-A | Recovery of constituent cellulose ester | 伊士曼化工公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113813406-A | Nano-particles for treating atherosclerosis by MRI and chemical excitation photodynamic therapy | 南京鼓楼医院 | 2021-12-21 | — | — | CN | disclosed |
| US-20030045461-A1 | Composition and methods of esterified nitroxides gated with carboxylic acids | SYNZYME TECHNOLOGIES, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20020045584-A1 | Acyclic isoprenoid ether derivatives as chemotherapeutics | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-04-18 | — | — | US | disclosed |
| WO-2002005856-A2 | ACYCLIC ISOPRENOID ETHER DERIVATIVES AS CHEMOTHERAPUETICS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5393776-A | Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0571928-A1 | Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0476493-A1 | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4740449-A | Optical recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-04-26 | — | — | US | disclosed |
| EP-0122523-A2 | Diazotype compositions and materials | Andrews Paper and Chemical Co., Inc. (US) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045461-A1 | Composition and methods of esterified nitroxides gated with carboxylic acids | FPGS, NDUFAB1, ARG2 | CA2 396/4885ALDH1A1 1001/4885HPGD 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.